Scripps inks $100M research pact with Pfizer

Pfizer will pay Scripps Research Institute $20 million a year for five years to help develop new therapies for diabetes, cancer, mental diseases and other conditions. The deal marks a big payoff for Florida's decision to woo Scripps into establishing a new research center in the state with $310 million in support. Scripps officials also noted that they stand to earn royalties on any approved products, but were quick to add that they were years away from seeing any of that money. The pact--touted during the pharma giant's presentation to analysts yesterday--marries Scripps' research talent with Pfizer's ability to bring new products to market. And it gives Scripps a big annual revenue boost that it can use to hire new scientists and purchase new lab equipment. Pfizer will get first right of refusal on about half of the discoveries that emerge from Scripps.

- check out the press release on the new deal
- here's the report on the pact from the Sun-Sentinel

ALSO: Pfizer also told analysts that it planned to file for approval of torcetrapib next year. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.